In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
|Articles|February 9, 2022
Daily OTC Pearl: Vazalore
Author(s)Saro Arakelians, PharmD
Vazalore has been shown to cause fewer stomach-related adverse effects than traditional aspirin.
Advertisement
OTC/Lifestyle Pearl of the Day: Vazalore
Indication: Valazore, a new type of aspirin, is a non-steroidal anti-inflammatory drug approved by the FDA in March 2021 as an OTC product that helps prevent blood clots.
Insight:
- Classified as a salicylate.
- Compared to traditional aspirin, Vazalore has been shown to cause fewer stomach-related adverse effects, such as ulcers and damage to the stomach.
- Dosing: Coronary artery bypass graft 325 mg once daily (start 6 hours after procedure) for 1 year. Percutaneous transluminal coronary angioplasty 325 mg 2 hours before surgery, then 160 mg–325 mg once daily. Carotid endarterectomy 80 mg once daily to 650 mg twice daily (start before surgery).
- The higher dose of Vazalore (325 mg) works by blocking certain chemicals in the body that cause pain, fever, and swelling.
- Caution: Do not take if history of bleeding and speak to the provider before starting the medication.
- If pregnant, discuss the use of Vazalore with a health care provider first.
- Available dosage: Caps 81 mg—12, 30; 325 mg—30.
Sources:
Advertisement
Related to this article
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
3
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5